KALY- Kali-Extracts Announces New Analyst Report Speculating $0.05 PPS Following Recent Biopharma Cannabis Extract Updates
August 28 2019 - 9:00AM
InvestorsHub NewsWire
KALY- Kali-Extracts Announces New
Analyst Report Speculating $0.05 PPS Following Recent Biopharma
Cannabis Extract Updates
Dallas, TX --
August 28, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc.
(Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today announced a new analyst report covering
the company’s recent biopharmaceutical cannabis extract business
development updates. The report has been released by Goldman
Small Cap Research after market today, August 27,
2019, and can be found on Goldman’s website
www.goldmanresearch.com. The report speculates a
potential KALY price per share of $0.05.
“Already
generating major revenue growth and operating profit, a series of
near-term revenue and pharmaceutical development milestones by KALY
warrant a closer look by investors as these shares could trade to
the $0.05 level in the near term”
The analyst
report update initiative was triggered by KALY’s recent CEO update
on the company’s cannabis extract biopharmaceutical business
pursuing $170 billion in pharmaceutical treatments where the CEO
announced new patent and trademark
applications on KALY’s CBD Formulation for the
treatment of Chronic Obstructive Pulmonary Disease (COPD).
The report includes coverage on the impact of the company’s
recently announced CBD extraction contracts with hemp farming
operations worth $15 million, and coverage of the company’s
recently posted 2019 YTD financials reporting 250% revenue
growth. The analyst report also
addresses KALY’s ongoing business partnership with Puration, Inc.
(USOTC:
PURA) and the sales of KALY’s Hemp4mula CBD candy line through
North American Cannabis Holdings, Inc’s (USOTC:
USMJ) ecommerce site www.usmj.com.
“When we
last left Kali, Inc. (OTC
– KALY – NR) dba/Kali-Extracts, Inc. in January 2019,
the Company was full of promise and in our view, well-positioned to
emerge as a future leader in its key segments of the CBD arena.
Seven months later, KALY has dramatically exceeded our expectations
with respect to revenue and new business, along with product
development and its overall industry positioning. The successes on
the product development and commercialization fronts appear to
serve as potential catalysts to favorably impact KALY’s stock and
valuation, thus affirming the value of its current and future
IP.”
To view the full
report visit https://www.goldmanresearch.com/
To learn more
about the company visit https://www.kali-extracts.com/
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and as such, may involve risks and uncertainties.
These forward looking statements relate to, amongst other things,
current expectation of the business environment in which the
company operates, potential future performance, projections of
future performance and the perceived opportunities in the market.
The company's actual performance, results and achievements may
differ materially from the expressed or implied in such
forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024